Micro X : MX1 Company Presentation

Micro-X Limited, ABN 21 153 273 735

For personal use only

COMPANY PRESENTATION

Micro-X management attending corporate, partnering and investor meetings in the EU and US

Adelaide, Australia, 21 March 2022: Australian hi-tech company Micro-X Ltd (ASX:MX1) (Micro-X or the Company), a leader in cold cathode x-ray technology for health and security markets globally, advises that Company's management including CEO, Peter Rowland and CFO, Kingsley Hall will be attending a number of corporate, partnering and investor meetings in the EU and the United States.

The meetings are primarily related to commercial distribution partnerships for its Mobile DR product range and the global launch of the Argus, the Company's IED X-ray camera.

The Company's Presentation for use in these meetings is attached.

This ASX Announcement is authorised by the Board of Micro-X.

- ENDS -

About Micro-X

Micro-X Limited (the Company) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-servicex-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: www.micro-x.com

CONTACTS

Micro-X Limited		Investor Enquiries
Peter Rowland, Managing Director		David Allen / John Granger
Kingsley Hall, CFO and Company Secretary		Hawkesbury Partners
		Tel: [phone]
Tel: [phone]		E: [e-mail]
E: [e-mail]		[e-mail]

Micro-X Limited, ABN 21 153 273 735, 1284 South Road, Tonsley, South Australia, 5042, AUSTRALIA

www.micro-x.com

ersonal use only

A C N 1 5 3 2 7 3 7 3 5 / A S X : M X 1

C O R P O R AT E

P R E S E N TAT I O N

CLEAR VISION FOCUSED EXECUTION

21 March2022

Peter Rowland

Managing Director & CEO

Kingsley Hall

CFO & Company Secretary

I M P O R TA N T N O T I C E

ersonal use only

S C O P E & L I M I T A T I O N S

This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

F O R W A R D L O O K I N G I N F O R M A T I O N

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and in formation are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

N O T A N O F F E R F O R S E C U R I T I E S

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

U N I T E D S T A T E S

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

O T H E R J U R I S D I C T I O N S

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

2

ersonal use only

M I N I A T U R I Z I N G X - R A Y

First Mover in Next Generation X-ray for Global Health and Security Markets

Platform technology in cold cathode x-ray

• X-rayproducts with significant reduction in size, weight and power
• Patented technology - platform for health and new security applications
• First to market with proven cold cathode medical x-ray product

25kg

Comparison

Conventional x-ray tube and Micro-Xx-ray tube

3

C O L D - C A T H O D E I S T H E F U T U R E O F X - R A Y

ersonal use only

Strong technology advantages

1st

F I R S T T O M A R K E T

Micro-X is first to market with a proven, Cold Cathode, Medical X-Ray product

S O L I D S TAT E L E D

No more hot filaments -

the Edison light bulb

becomes solid-state LED

S U P E R I O R P E R F O R M A N C E

Proven performance, reliability

and lifetime of patented

technology in production in

Adelaide, Australia

E N O R M O U S P O S S I B I L I T E S

Huge opportunities for new products with this technology

'" We are five years ahead of the competition, which drives the pace of our commercialization"

- Peter Rowland, CEO and Managing Director

4